Literature DB >> 10802278

Vaginal epithelial surface appearances in women using vaginal rings for contraception.

I S Fraser1, M Lacarra, D R Mishell, F Alvarez, V Brache, P Lähteenmäki, K Elomaa, E Weisberg, H A Nash.   

Abstract

Vaginal inspections using colposcopy before insertion of contraceptive vaginal rings and at 2-month intervals during ring use were conducted on 169 users of four different formulations. The rings studied released Nestorone alone (50, 75, 100 g daily over 6 months); ethinyl estradiol: Nestorone (30:100 and 15:150 g daily over 6 months); ethinylestradiol:norethindrone acetate (20:1000 and 15:1000 g daily over 4 months); and ethinyl estradiol:norethindrone acetate (20:1000 g daily over 12 months). A total of 88 altered or atypical conditions of the vaginal surface appearance were recorded in 507 inspections (17.4% of inspections). Many of these atypical appearances were quite subtle. The incidence was significantly higher (p <0.01) than in the single pretreatment examinations (11 in 158 inspections; 7.0%), but closely matched that of a "control group" of sexually active women who were the subject of an earlier study by the same investigators. In that study, the incidence was 18% (57 atypical conditions in 317 inspections). In all, 83% of atypical conditions identified in the vagina during ring use had disappeared by the next scheduled colposcopy despite continued ring use. Findings of potential significance were conservatively defined as all ulcerations, those abrasions and ecchymoses that were >0.5 cm in any direction, and fields of five or more petechiae. Findings fitting those criteria comprised 30% of atypical conditions in ring users, 33% in the control group, and 27% pretreatment. The corresponding incidence as a percentage of inspections were 5.3%, 6. 0%, and 2.5% in the ring users, control groups, and pretreatment groups, respectively. These differences were not statistically significant. The findings suggest that the vaginal rings included in the studies contributed little, if at all, to clinically significant lesions or to total lesion incidence. Further definition would require a larger and longer-term study with matched controls.

Entities:  

Keywords:  Americas; Australia; Caribbean; Clinical Research; Colposcopy; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Developed Countries; Developing Countries; Diseases; Dominican Republic; Endoscopy; Ethinyl Estradiol; Europe; Examinations And Diagnoses; Family Planning; Finland; Latin America; Norethindrone; Norethindrone Acetate; North America; Northern America; Northern Europe; Oceania; Physical Examinations And Diagnoses; Research Methodology; Research Report; Scandinavia; United States; Vaginal Abnormalities; Vaginal Rings

Mesh:

Substances:

Year:  2000        PMID: 10802278     DOI: 10.1016/s0010-7824(00)00081-0

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Segesterone acetate/ethinyl estradiol 12-month contraceptive vaginal system safety evaluation.

Authors:  Kristina Gemzell-Danielsson; Regine Sitruk-Ware; Mitchell D Creinin; Michael Thomas; Kurt T Barnhart; George Creasy; Heather Sussman; Mohcine Alami; Anne E Burke; Edith Weisberg; Ian Fraser; Marie-José Miranda; Melissa Gilliam; James Liu; Bruce R Carr; Marlena Plagianos; Kevin Roberts; Diana Blithe
Journal:  Contraception       Date:  2019-03-01       Impact factor: 3.375

2.  Examining the efficacy, safety, and patient acceptability of the combined contraceptive vaginal ring (NuvaRing).

Authors:  Devorah R Wieder; Lynn Pattimakiel
Journal:  Int J Womens Health       Date:  2010-11-12

3.  A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.

Authors:  Todd J Johnson; Meredith R Clark; Theodore H Albright; Joel S Nebeker; Anthony L Tuitupou; Justin T Clark; Judit Fabian; R Tyler McCabe; Neelima Chandra; Gustavo F Doncel; David R Friend; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

4.  Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.

Authors:  Krishnaveni Reddy; Cliff Kelly; Elizabeth R Brown; Nitesha Jeenarain; Logashvari Naidoo; Samantha Siva; Linda-Gail Bekker; Gonasagrie Nair; Bonus Makanani; Lameck Chinula; Nyaradzo Mgodi; Zvavahera Chirenje; Flavia Matovu Kiweewa; Jeanne Marrazzo; Katherine Bunge; Lydia Soto-Torres; Jeanna Piper; Jared M Baeten; Thesla Palanee-Phillips
Journal:  AIDS       Date:  2020-03-15       Impact factor: 4.632

Review 5.  Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies.

Authors:  Andrea Ries Thurman; Meredith R Clark; Jennifer A Hurlburt; Gustavo F Doncel
Journal:  Int J Womens Health       Date:  2013-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.